Halozyme Therapeutics (HALO) Free Cash Flow Growth (1y) (2011 - 2026)
Halozyme Therapeutics (HALO) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
814,307.08 Bn |
814,307.05 Bn |
- |
- |
| 2 |
Belite Bio |
55,320.00 Bn |
55,320.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,149.72 Bn |
17,149.72 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
3,590.00 Bn |
3,589.71 Bn |
242.10 Mn |
88.70% |
| 5 |
Akari Therapeutics |
1,650.72 Bn |
1,650.72 Bn |
- |
-15.72% |
| 6 |
Evaxion A |
1,522.09 Bn |
1,522.07 Bn |
- |
- |
| 7 |
Psyence Biomedical |
229.39 Bn |
229.38 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.09 Bn |
105.85 Bn |
2.59 Bn |
66.37% |
| 9 |
Abivax |
90.15 Bn |
90.15 Bn |
- |
- |
| 10 |
Halozyme Therapeutics |
8.24 Bn |
7.92 Bn |
297.47 Mn |
14.70% |
| Date | Value |
|---|
| Mar 31, 2026 |
14.70% |
| Dec 31, 2025 |
27.51% |
| Sep 30, 2025 |
54.20% |
| Jun 30, 2025 |
90.86% |
| Mar 31, 2025 |
20.19% |
| Dec 31, 2024 |
100.26% |
| Sep 30, 2024 |
-14.09% |
| Jun 30, 2024 |
-34.01% |
| Mar 31, 2024 |
69.22% |
| Dec 31, 2023 |
9.34% |
| Sep 30, 2023 |
93.12% |
| Jun 30, 2023 |
97.58% |
| Mar 31, 2023 |
59.78% |
| Dec 31, 2022 |
-2.73% |
| Sep 30, 2022 |
-43.40% |
| Jun 30, 2022 |
7.93% |
| Mar 31, 2022 |
-18.45% |
| Dec 31, 2021 |
60.44% |
| Sep 30, 2021 |
2,023.72% |
| Jun 30, 2021 |
1,018.51% |
